Trio Face 11 Year Wait On Eliquis As US Patents Upheld
Key Formulation Patent Stands Strong Against Attack From Three Firms
Executive Summary
Three ANDA sponsors – HEC’s Sunshine Lake, Sigmapharm and Unichem – for generic versions of Eliquis had elected to take their Hatch-Waxman case to trial but were soundly beaten by originator’s Bristol-Myers Squibb and Pfizer. A launch in 2031 could now be their best, and only, option.
You may also be interested in...
Stockwatch: Second-Quarter Earnings Highlight The Duracell Bunny PD-1 Inhibitor Race Winner
After the differing second-quarter financial performances of Roche, AstraZeneca and Pfizer’s oncology franchises, the reports by Merck & Co and BMS should have helped define the effects of the pandemic on oncology businesses.
First US Eliquis Generics Face Six-Year Wait
Mylan and Micro Labs have received the first FDA approvals for generic rivals to BMS’ Eliquis oral anticoagulant. However, as a result of the firms’ settlements with the originator, BMS does not expect the generics to hit the US market until 2026.
Teligent Announces $140m Operating Loss As Plant Woes Continue
Struggling Teligent underlined the importance of lifting the FDA Warning Letter against its key manufacturing facility in Buena, New Jersey, as its impact slammed the company’s operations last year.